Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAINASDAQ:NMRANASDAQ:PRTCNASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Life Sciences$2.47+0.2%$1.61$1.03▼$2.64$495.64M1.221.65 million shs1.91 million shsNMRANeumora Therapeutics$0.81+2.7%$0.73$0.61▼$17.19$131.18M2.731.51 million shs467,667 shsPRTCPureTech Health$18.77+0.9%$17.25$13.30▼$29.80$450.84M1.144,686 shs1,484 shsSIGASIGA Technologies$5.88-4.4%$5.88$4.95▼$12.83$419.93M0.93730,547 shs456,549 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Life Sciences+5.11%+6.93%+68.03%+57.32%+60.39%NMRANeumora Therapeutics+6.31%+10.43%+13.25%-48.03%-92.10%PRTCPureTech Health+1.17%+4.49%+4.26%+0.10%-38.31%SIGASIGA Technologies-0.81%+0.99%+13.89%+7.71%-17.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIAtai Life Sciences2.5446 of 5 stars3.71.00.00.02.92.50.6NMRANeumora Therapeutics2.8853 of 5 stars4.10.00.00.02.62.51.3PRTCPureTech Health2.4679 of 5 stars3.85.00.00.02.20.00.0SIGASIGA Technologies2.4406 of 5 stars0.03.00.00.02.80.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Life Sciences 3.33Buy$8.67250.31% UpsideNMRANeumora Therapeutics 2.22Hold$9.291,044.97% UpsidePRTCPureTech Health 3.50Strong Buy$45.00139.74% UpsideSIGASIGA Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NMRA, PRTC, SIGA, and ATAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025ATAIAtai Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.005/20/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/13/2025ATAIAtai Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/10/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/2/2025NMRANeumora TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$7.00 ➝ $1.003/19/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/10/2025NMRANeumora TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/7/2025NMRANeumora TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/7/2025NMRANeumora TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.00 ➝ $2.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Life Sciences$1.86M266.04N/AN/A$1.47 per share1.68NMRANeumora TherapeuticsN/AN/AN/AN/A$3.07 per shareN/APRTCPureTech Health$4.32M104.48N/AN/A$16.94 per share1.11SIGASIGA Technologies$120.33M3.49$0.93 per share6.34$2.77 per share2.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Life Sciences-$40.22M-$0.91N/AN/AN/AN/A-65.75%-52.71%8/12/2025 (Estimated)NMRANeumora Therapeutics-$235.93M-$1.61N/AN/AN/AN/A-73.63%-68.97%8/5/2025 (Estimated)PRTCPureTech Health-$65.70MN/A0.00N/AN/AN/AN/AN/AN/ASIGASIGA Technologies$68.07M$0.674.904.70N/A49.33%49.06%38.72%7/30/2025 (Estimated)Latest NMRA, PRTC, SIGA, and ATAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ATAIAtai Life Sciences-$0.19-$0.15+$0.04-$0.15N/A$1.56 million5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A5/8/2025Q1 2025SIGASIGA TechnologiesN/A-$0.01N/A-$0.01N/A$7.04 million3/17/2025Q4 2024ATAIAtai Life Sciences-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million3/11/2025Q4 2024SIGASIGA TechnologiesN/A$0.63N/A$0.63N/A$81.40 million3/6/2025Q4 2024NMRANeumora Therapeutics-$0.46-$0.37+$0.09-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai Life SciencesN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ALatest NMRA, PRTC, SIGA, and ATAI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/8/2025SIGASIGA Technologiesspecial$0.604/29/20254/29/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai Life Sciences0.145.815.81NMRANeumora TherapeuticsN/A10.9810.98PRTCPureTech HealthN/A3.68N/ASIGASIGA TechnologiesN/A8.105.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Life Sciences28.41%NMRANeumora Therapeutics47.65%PRTCPureTech Health0.04%SIGASIGA Technologies55.40%Insider OwnershipCompanyInsider OwnershipATAIAtai Life Sciences31.20%NMRANeumora Therapeutics26.80%PRTCPureTech Health5.30%SIGASIGA Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Life Sciences80200.34 million115.45 millionOptionableNMRANeumora Therapeutics108161.75 million118.91 millionOptionablePRTCPureTech Health10024.02 million22.67 millionNot OptionableSIGASIGA Technologies4071.44 million70.31 millionOptionableNMRA, PRTC, SIGA, and ATAI HeadlinesRecent News About These CompaniesSIGA Technologies, Inc. (NASDAQ:SIGA) Short Interest Down 12.5% in MayJune 4 at 4:56 PM | marketbeat.comTraders Purchase Large Volume of SIGA Technologies Call Options (NASDAQ:SIGA)May 30, 2025 | marketbeat.comSIGA Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)May 30, 2025 | americanbankingnews.comD. E. Shaw & Co. Inc. Sells 87,853 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)May 21, 2025 | marketbeat.comStock Traders Purchase Large Volume of SIGA Technologies Call Options (NASDAQ:SIGA)May 17, 2025 | marketbeat.comWe Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster EarningsMay 16, 2025 | finance.yahoo.comUndiscovered Gems in the US Market for May 2025May 16, 2025 | finance.yahoo.comSIGA Technologies (NASDAQ:SIGA) Issues Quarterly Earnings ResultsMay 12, 2025 | marketbeat.comDimensional Fund Advisors LP Raises Stock Position in SIGA Technologies, Inc. (NASDAQ:SIGA)May 12, 2025 | marketbeat.comSIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)May 10, 2025 | finance.yahoo.comSIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comSIGA Reports Financial Results for Three Months Ended March 31, 2025May 8, 2025 | globenewswire.comCalculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)May 2, 2025 | finance.yahoo.comSiga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for InvestorsMay 1, 2025 | zacks.comSIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 ResultsMay 1, 2025 | globenewswire.comChiliz joins SIGA to help drive integrity in sportApril 30, 2025 | en.as.comWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Down 11.34%April 29, 2025 | aaii.comHere's Why Siga Technologies Inc. (SIGA) Gained But Lagged the Market TodayApril 25, 2025 | zacks.comSiga Technologies Inc. (SIGA) Outperforms Broader Market: What You Need to KnowApril 23, 2025 | zacks.comSiga Technologies Inc. (SIGA) Stock Moves -1.82%: What You Should KnowApril 17, 2025 | msn.com3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield (SIGA)April 16, 2025 | dividendstocks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNMRA, PRTC, SIGA, and ATAI Company DescriptionsAtai Life Sciences NASDAQ:ATAI$2.47 +0.00 (+0.16%) Closing price 03:59 PM EasternExtended Trading$2.48 +0.00 (+0.04%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Neumora Therapeutics NASDAQ:NMRA$0.81 +0.02 (+2.66%) Closing price 03:59 PM EasternExtended Trading$0.80 -0.02 (-1.97%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.PureTech Health NASDAQ:PRTC$18.69 +0.09 (+0.48%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.SIGA Technologies NASDAQ:SIGA$5.88 -0.27 (-4.42%) Closing price 03:59 PM EasternExtended Trading$5.87 -0.01 (-0.14%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
